Literature DB >> 10810466

Primary fibrosarcoma of bone. Outcome after primary surgical treatment.

P J Papagelopoulos1, E Galanis, F J Frassica, F H Sim, D R Larson, L E Wold.   

Abstract

To investigate outcome and evaluate prognostic factors in primary fibrosarcoma of bone, all patients at the authors' institution who had surgical treatment for primary fibrosarcoma of bone from 1910 to 1995 were studied. Medical records, surgical reports, radiographs, and histologic slides of 92 patients (51 males, 41 females; mean age, 38 years; range, 8-84 years) were reviewed. The most common tumor locations were the femur (28 patients), tibia (21 patients), and pelvis (14 patients). Sixty-one tumors (66%) were Enneking Stage IIB. Twenty-nine patients (31.5%) had adjuvant therapy: 16 had radiation, nine had chemotherapy alone, and four had radiation and chemotherapy. Amputation or disarticulation was performed in 61 patients (66%), wide excision was performed in 13 (14%), marginal excision was performed in 15 (16%), and intralesional excision was performed in three (3.3%). Local recurrence occurred in 14 patients (15%) at a median time of 7 months (range, 3-21 months). Metastases developed in 58 of the 85 patients (68%) with Stage I or II tumors at presentation, at a median of 9 months (range, 1-51 months). Survivorship analysis showed that the overall probability of survival was 33.4% at 5 years after surgery. Multivariate analysis showed that the main prognostic risk factors affecting overall survival included age older than 40 years, tumor location in the axial skeleton, and high-grade tumor (Grade 3 or 4). With the high incidence of systemic failure after surgical treatment, perioperative adjuvant treatment modalities should be considered.

Entities:  

Mesh:

Year:  2000        PMID: 10810466

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  9 in total

1.  A rare case of locally advanced fibrosarcoma of diaphysal humerus managed successfully with limb-sparing procedures after neoadjuvant chemotherapy.

Authors:  Omar El Mesbahi; Samia Arifi; Zineb Benbrahim; Abdelhalim El Ibrahimi; Fouad Kettani; Amal Bennani; Afaf Amarti; My Youssef Alaoui Lamrani; Siham Tizniti; Abdelmajid El Mrini
Journal:  World J Surg Oncol       Date:  2010-09-06       Impact factor: 2.754

2.  Recurrent adult-type fibrosarcoma of the frontal bone in a child.

Authors:  Mariangela Novello; Concezio Di Rocco; Gianpiero Tamburrini; Paolo Frassanito; Daniel T Aguirre; Andrew E Rosenberg; Antonella Coli
Journal:  Childs Nerv Syst       Date:  2016-01-07       Impact factor: 1.475

3.  Huaier aqueous extract induces apoptosis of human fibrosarcoma HT1080 cells through the mitochondrial pathway.

Authors:  Yang Cui; Hongmei Meng; Weidong Liu; Huan Wang; Qingpeng Liu
Journal:  Oncol Lett       Date:  2015-01-27       Impact factor: 2.967

4.  Prognostic Nomogram and a Risk Classification System for Predicting Overall Survival of Elderly Patients with Fibrosarcoma: A Population-Based Study.

Authors:  Fengkai Yang; Hangkai Xie; Yucheng Wang
Journal:  J Oncol       Date:  2021-09-18       Impact factor: 4.375

5.  Secretion of MCP-1 and other paracrine factors in a novel tumor-bone coculture model.

Authors:  Katherine R Schiller; Marion R Zillhardt; Jeremy Alley; Dori L Borjesson; Alvin J Beitz; Laura J Mauro
Journal:  BMC Cancer       Date:  2009-02-03       Impact factor: 4.430

6.  Metastatic secondary fibrosarcoma of bone responsive to repeated courses of Ifosfamide and associated with hypoglycemia.

Authors:  Elaine S Bouttell; N Wilson Rodger; Vivien H C Bramwell
Journal:  Sarcoma       Date:  2003

7.  Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in adult human sarcoma cell lines.

Authors:  M Waheed Roomi; Tatiana Kalinovsky; Aleksandra Niedzwiecki; Matthias Rath
Journal:  Int J Oncol       Date:  2013-05-09       Impact factor: 5.650

8.  In vitro modulation of MMP-2 and MMP-9 in adult human sarcoma cell lines by cytokines, inducers and inhibitors.

Authors:  M W Roomi; T Kalinovsky; J Monterrey; M Rath; A Niedzwiecki
Journal:  Int J Oncol       Date:  2013-09-30       Impact factor: 5.650

9.  Peroxiredoxin 1 (PRDX1) Suppresses Progressions and Metastasis of Osteosarcoma and Fibrosarcoma of Bone.

Authors:  Yongxiang Wang; Mingfa Liu; Peng Yang; Hao Peng
Journal:  Med Sci Monit       Date:  2018-06-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.